Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials
COVID-19 pandemic demands a swift response to find therapeutic tools that effectively reduce morbidity and mortality. Despite initial fears, evidence from retrospective observational studies supports the inhibition of the renin-angiotensin system as an emerging pathway to delay or moderate angiotens...
Saved in:
Main Authors: | Rodolfo Pedro Rothlin (Author), Mariano Duarte (Author), Facundo Germán Pelorosso (Author), Liliana Nicolosi (Author), M. Victoria Salgado (Author), Héctor Miguel Vetulli (Author), Eduardo Spitzer (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19
by: Rodolfo Pedro Rothlin, et al.
Published: (2023) -
The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
by: Myla E. Moretti, et al.
Published: (2012) -
Clinical pharmacogenetics of angiotensin II receptor blockers in Iraq
by: Hany A Al-Hussaniy, et al.
Published: (2023) -
Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Contrast-Induced Nephropathy
by: Letian Zhou, et al.
Published: (2014) -
Early prophylaxis of cardiomyopathy with beta-blockers and angiotensin receptor blockers in patients with Duchenne muscular dystrophy
by: Heirim Lee, et al.
Published: (2022)